Verastem, Inc.
VSTMStock
$5.77+17.18%52W
Market Cap$503.52M
P/E—
Div yield—
Beta0.42
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.46%
Price vs S&P 500 (4W)42.30%
VGM Score49.29
Market Capitalization$503.52M
Earnings Surprise History
Q1 26-0.46est. -0.47
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VSTMVerastem, Inc. | D | C | C | $5.77 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Verastem Inc is a late-stage development biopharmaceutical company developing novel anticancer agents targeting critical signaling pathways in cancer. The company's pipeline is focused on RAF/MEK and FAK inhibition to suppress cancer cell survival and tumor growth.